Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MAK683 in adult patients with advanced malignancies
jRCT2080223438Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of MAK683 in non-Hodgkin lymphoma (NHL), nasopharyngeal carcinoma (NPC), prostate cancer (PCa) and 3 more, sponsored by Novartis. Started Jan 2017; status: completed.
02
Drugs
MAK683
03
Conditions
non-Hodgkin lymphoma (NHL)nasopharyngeal carcinoma (NPC)prostate cancer (PCa)gastric cancer (GC)clear cell ovarian cancer
Beyond the preview
Go deeper on jRCT2080223438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223438.